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Background: The European Union (EU) health mandate was initially defined in the Maastricht Treaty in 1992. The
twentieth anniversary of the Treaty offers a unique opportunity to take stock of EU health actions by giving an overview
of influential public health related EU-level policy outputs and a summary of policy outputs or actions perceived as an
achievement, a failure or a missed opportunity.
Methods: Semi-structured expert interviews (N = 20) were conducted focusing on EU-level actions that were relevant for
health. Respondents were asked to name EU policies or actions that they perceived as an achievement, a failure or a
missed opportunity. A directed content analysis approach was used to identify expert perceptions on achievements,
failures and missed opportunities in the interviews. Additionally, a nominal group technique was applied to identify
influential and public health relevant EU-level policy outputs.
Results: The ranking of influential policy outputs resulted in top positions of adjudications and legislations, agencies,
European Commission (EC) programmes and strategies, official networks, cooperative structures and exchange efforts,
the work on health determinants and uptake of scientific knowledge. The assessment of EU health policies as being
an achievement, a failure or a missed opportunity was often characterized by diverging respondent views. Recurring
topics that emerged were the Directorate General for Health and Consumers (DG SANCO), EU agencies, life style
factors, internal market provisions as well as the EU Directive on patients’ rights in cross-border healthcare. Among
these recurring topics, expert perceptions on the establishment of DG SANCO, EU public health agencies, and successes
in tobacco control were dominated by aspects of achievements. The implementation status of the Health in All
Policy approach was perceived as a missed opportunity.
Conclusions: When comparing the emerging themes from the interviews conducted with the responsibilities
defined in the EU health mandate, one can identify that these responsibilities were only partly fulfilled or
acknowledged by the respondents. In general, the EU is a recognized public health player in Europe which over
the past two decades, has begun to develop competencies in supporting, coordinating and supplementing
member state health actions. However, the assurance of health protection in other European policies seems to
require further development.
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The Maastricht Treaty from 1992 marked the beginning
of the health mandate of the European Union (EU) as
enshrined today in Article 168 of the Lisbon Treaty (TFEU,
Treaty on the Functioning of the European Union) [1]. The
original EU health mandate focused primarily on stimu-
lating cooperation between member states and supporting
national actions (Art. 129 (1), Treaty of the European
Union (TEU)) [2]. It embodied the Union with only lim-
ited legislative powers on health matters. Although this
initial mandate was enhanced through subsequent
Treaties, today Article 168, still gives the EU relatively
circumscribed power in areas of public health (Art. 168
(4), TFEU). Healthcare continues to remain a national
competence and in this regard, the EU “shall respect the
responsibilities of the member states for the definition of
their health policy and for the organization and delivery
of their health services” (Art. 168 (7), TFEU). Despite
the restricted Treaty-based mandate for health, the EU
has a relevant role to play in national public health and
health systems policies and has expanded its remit in areas
beyond the Treaty [3]. Areas affected by EU provisions are
extensively described in the literature [4-11]. To illus-
trate the main developments in the area of what can
be called “EU health policy” a timeline is illustrated in
Table 1. However, because of its limited legal mandate,
some EU legal initiatives were highly contested [12,13].
Therefore, one can pose the question of what has been
achieved over the last twenty years. It may be argued that,Table 1 Timeline of main developments in EU health policy
Year EU health policy developments before the introduction of a lega
1957 Treaty of Rome: health is not a priority. Two aspects are considered: s
1971 Regulation (EEC) 1408/71 on the application of social security scheme
(accompanied by implementing Regulation (EEC) No 574/72).
1985 EC launches the action programme “Europe against Cancer”.
1993 Maastricht treaty: the legal basis for undertaking actions in the field o
Year EU health policy developments after the introduction of a legal
1995 The European Agency for the Evaluation of Medicinal Products (EMEA
1997 Treaty of Amsterdam: Health Impact Assessment is implemented.
1999 Directorate General for Health and Consumers (DG SANCO) is establis
2000 Lisbon Agenda recognizes health protection as a prerequisite for econ
2002 The European Food Safety Authority (EFSA) has been established in P
2002 First Programme of Community action in the field of public health (20
2003 The Tobacco Advertising Directive 2003/ 33/EC is adopted after the fi
2004 Commission decision to set up an Executive Agency for the public he
field of public health.
2005 The European Centre for Disease Prevention and Control (ECDC) in St
2007 White paper: Together for health: a strategic approach for the EU 200
2007 Decision for a second Programme of Community action in the field o
2011 Directive 2011/24/EU on the application of patients’ rights in cross-bodespite its narrow legislative scope, the health mandate
has triggered important European actions in certain public
health areas like tobacco control [14,15], infectious disease
control [16,17], European guidelines [18-20] and the de-
velopment of an EU public health infrastructure [21]. In
recent years, the EC has summarized in annual reports a
diverse nature of key public health achievements such as
communications and recommendations, health policies,
EC co-financed actions and established networks (e.g. high
level groups, scientific committees, platforms) [22-24].
However, stakeholders in the field provide examples
indicating that public health relevant EU policies such
as single EU policy assessments on the Common Agricul-
ture Policy (CAP) [25,26], pharmaceuticals [27], or the
Health in All Policy (HiAP) approach [28] do not always
meet the expectations of the public health community. In
these papers the authors express concerns about poten-
tially detrimental health effects [25,26] or disappointment
about the support of the policies and approaches aimed
at improving health in Europe [27,28]. Also, EU agencies
such as the European Centre for Disease Prevention and
Control (ECDC) are described as agencies with a limited
legal mandate, competences and resources for EU public
health but, at the same time, with promising prospects
to develop as a renowned international player in the
field [29].
In addition, an evaluation of the EU Health Strategy
acknowledges its status as a guiding framework for EC
health policies and joint EC and member state actionsl EU health mandate
ocial security of cross-border workers and occupational health.
s to employed persons and their families moving within the community
f public health is defined in Article 3(o) and Article 129.
EU health mandate by the Maastricht Treaty
), now European Medicines Agency (EMA), has been formed in London.
hed.
omic growth measured with the indicator Healthy Life Years.
arma.
03-2008) launched.
rst version has been annulled by the European Court of Justice.




rder healthcare has been adopted.
Table 2 Professional functions of interviewed participants
Function Number of participants
EU/national civil servant 7
EU/national politician 2
Academia 5
Public health advisor/advocate 6
Total 20
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Strategy on other EC policies as well as on member state
health policies and actions [30]. Evaluations of the EU
public health programmes, which are one of the EC’s
financial instruments to implement its strategic health
goals, criticize missing prioritization of topics, barriers
for participation in projects for some member states
and ineffective dissemination of project results [31,32].
Hence, the available evidence of the impact of EU health
policies, infrastructure, and actions is elusive, and the
identification of the value of public health relevant
EU-level actions across all policies is lacking.
In this paper, we aim to explore and provide an over-
view of influential public health relevant EU-level policy
outputs and a summary of policy outputs or actions per-
ceived as an achievement, a failure or a missed oppor-
tunity by interviewing key experts in the field. By this,
we intend to establish a qualitative indication of which
EU health policies have contributed to the improvement
of population health in Europe.
Methods
The study focused on the evolvement of the health
mandate since 1992, the year the Maastricht Treaty was
signed. The study was carried out in two consecutive
phases: (1) qualitative interviews, suitable to identify
expert perceptions, and (2) voting on influential and
public health relevant EU policy outputs and actions based
on nominal group technique. The study adhered to the
RATS guidelines on qualitative research [33].
Study participants
Experts were purposely selected to ensure heterogeneity
of opinions. The selection was based on their individual
profile and professional affiliation. We selected experts
that were renowned in the field due to their current or
former affiliation to specific EU-level bodies and institu-
tions, research institutes with EU focus, or EU-level non-
governmental organization. Selected experts were actively
involved in public health research, policy-making, policy
advice or advocacy performed at EU level, internally or
externally. In addition, snowball sampling was applied
until data saturation was reached. Data saturation was
assumed as soon as no new EU public health policy
actions and their perceptions were mentioned during
the interviews.
The potential participants were contacted between
December 2011 and March 2012 by a short information
email to identify whether they were interested to partici-
pate in the interview study. Of 22 contacted experts,
twenty participated in this study, one participant could
not confirm participation due to time constraints and
another did not respond to the invitation. Of those
twenty experts nine belonged to the initial purposivelyselected sample and eleven were identified during the
snowball sampling procedure based on recommenda-
tions of already interviewed experts. The majority of ex-
perts was affiliated to an institution located in Brussels
(n = 10). The composition of the study sample in terms
of represented professional affiliations is outlined in
Table 2.
Upon agreement by the participant, an appointment
for the interview was made and participants received an
informative letter with more in-depth information about
the goal of the study and an informed consent form in
which the voluntary basis of the participation has been
clarified and anonymized data handling was assured.
Qualitative interviews
Interviews were conducted either face-to-face (n = 4) or
via telephone, or Voice over IP (n = 16) in the period be-
tween January and March 2012 and were held in English,
Dutch or German by one of the three principal investi-
gators (NR, TC, KS). The interviews lasted from 35 to
90 minutes. All interviews were audio-recorded, tran-
scribed verbatim and anonymized.
The interviews were performed using a specifically
designed semi-structured interview guide. The guide was
developed on the basis of previous desktop research and
an internal brainstorming session of an advisory research
group consisting of the three principal investigators,
four senior researchers, and one junior researcher of
the Department of International Health at Maastricht
University to identify items relevant for investigating
expert perceptions on European public health policy. Dur-
ing the course of this process, a list of public health rele-
vant EU policy outputs, processes or procedures that were
regarded as achievements, failures or missed opportunities
were first gathered individually and then, following a
group discussion, a common list was compiled. This
output was used to construct the interview guide contain-
ing six guiding themes from which open-ended questions
were formulated. The guiding themes included (1) a de-
scription of the individual role of the expert in European
public health, (2) the individual definition of European
public health, (3) the assessment of public health relevant
EU-level actions as being an achievement, missed oppor-
tunity or failure, (4) the formulation of five influential
European policy outputs, (5) consequences of European
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level. The semi-structured interview guide was used as a
framework for the interviews and allowed the inter-
viewers to address other relevant topics that emerged
during the interviews.
Analysis
After completion of interviews the three principal inves-
tigators initially performed an internal analysis of each
separate interview and an analysis across interviews to
identify the scope of EU-level actions and experts’ percep-
tions of these actions as achievements, failures or missed
opportunities [34]. Afterwards, a directed (or deductive)
content analysis approach [35,36] was applied whereby
the initially predefined coding scheme with the main
categories of interest (achievement, failure, and missed
opportunity) was used to summarize the respective topics
and the reasoning that appeared during the interviews.
Topics that did not fit into one of these main categories
were added as new codes and were organized into new
categories. The analysis was jointly performed by the
principal investigators using NVivo 9 (QSR International
Pty Ltd. Version 9).
Furthermore, the results of the content analysis on
achievements, failures and missed opportunities were
grouped according to the major common themes in a
table to provide an overview of the perceptions of the
key informants. Prominent EU-level outputs or actions,
which were discussed by almost all respondents, are
described in more detail in the results section. Where
applicable, we used original quotes to illustrate the views
and tendencies of experts’ assessments. The professional
profile and study ID of respondents are indicated behind
the respective quotes. Quotes which were originally given
in Dutch or German were translated into English.
Nominal group technique
A slightly adapted nominal group technique [37] was used
for triangulation purposes. During the interviews, the
participants were asked for five influential policy out-
puts of European health policy-making. Following the
finalization of all interviews, all participant nominations
were compiled in one list and reoccurring topics were
removed. To ensure comparability of policy outputs and
actions, we grouped the nominations into categories under
the following headlines: (a) secondary legislation and court
decisions; (b) soft laws, strategies, and programmes;
(c) agencies, centres, organizations; (d) networks, policy
platforms, cooperation; and (e) others. Participants were
asked in an online survey to select three outputs per cat-
egory which were, according to their opinion, most influ-
ential. Based on the participants’ nominations, a ranking
in terms of a frequency distribution of selected influential
policy outputs for each category was determined. Theonline survey was completed by 18 out of 20 partici-
pants who took part in the interviews.
Ensuring quality
The design and analysis of the study was guided by ap-
plying Guba and Lincoln’s test for trustworthiness [38].
Credibility and dependability have been ensured by en-
larging the sample until saturation was reached in terms
of the identification of EU policy actions and their per-
ceptions. Moreover, three researchers in the primary re-
search group in combination with an internal advisory
research group were involved with the aim of reflecting
upon the study design and critically questioning the find-
ings. Additionally, the primary research group met regu-
larly during the interview period to exchange initial
findings and experiences on the interview process. The
members of the internal advisory research group were
experienced in EU public health policy research or quali-
tative research methodologies. The confirmability was
strengthened by the use of several investigators both in
the data collection process and in the analysis phase,
combined with the use of triangulation, where interview
participants were also asked to participate in the rank-
ing exercise.
Ethical considerations
The Medical Ethical Committee of the University Hos-
pital Maastricht and University Maastricht declared that
no ethical approval was required for this type of research.
All participants were informed about their role and rights
as study participant prior to their interview participation.
All participants provided written or audio-recorded in-
formed consent to be interviewed.
Results
Overall, respondents consistently mentioned that, during
the twenty-year history of the EU health mandate, spe-
cific initiators induced change in European public health
policy. The most important identified initiators included
the Maastricht Treaty with its later amendments, the
health-related rulings of the European Court of Justice,
and the health crises such as Boviene spongiforme ence-
falopathie (BSE) and Severe Acute Respiratory Syndrome
(SARS). In addition, the internal market provisions with
the foreseen free movement of goods, people, services
and capital, initiated change with both negative and
positive public health impact. Additionally, a set of con-
ditions was identified in the interviews that described
and advanced the role of EU health policy as a reference
point for public health. These conditions under which
EU health policy made progress during the past twenty
years were (i) the regulatory power at the EU-level, (ii)
EU-led facilitation of cooperation and comparisons
across member states; along with (iii) increased capacity
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alization, development of interest groups, associations).
Influential EU health policy outputs
The ranking of influential policy outputs of EU-level
health policy-making is provided in Table 3.
In the category “secondary legislation and court
decisions”, the patients’ rights decisions made by the
European Court of Justice (n = 12) were chosen by most
of the respondents as influential policy output, followed
by the Directive on the application of patients’ rights in
cross-border healthcare [39] (n = 10) and the Directive
on advertising and sponsorship of tobacco products [14]
(n = 9). In the category entitled “soft laws, strategies,
and programmes”, the first and second EU public health
programmes [40,41] (n = 9) were selected most frequently,
followed by the 2008–2013 health strategy “Together for
Health” [42] (n = 6). The third rank is shared by three
policy outputs: the “Framework for action in the field of
public health” [43] (n = 5) which is the Commission’s
first proposal setting out EU-level public health after the
introduction of the health mandate in the Maastricht
Treaty, the Council conclusions “Towards modern, re-
sponsive and sustainable health systems” [44] (n = 5),
and the current over-arching European strategy “Europe
2020” [45] (n = 5). In the third category on “agencies,
centres and organizations”, the European Medicines Agency
(EMA, n = 15) ranked top, followed by the ECDC (n = 13)
and the European Food Safety Authority (EFSA, n = 9).
Among “networks, policy platforms and collaborations”,
the European presidencies (n = 13) were selected most
often by the respondents, followed by the collaboration
of the European Commission (EC), the World Health
Organization Regional Office for Europe (WHO-EUR)
and the Organization for Economic Co-operation and
Development (OECD) (n = 8). Moreover, the three entries
on the third rank include the EU Health Policy Forum
(n = 6), the network on epidemiological surveillance and
control of infectious diseases (n = 6), and the network
on Health Technology Assessment (n = 6). The fifth cat-
egory was not topic specific therefore, work on European
level health determinants (n = 10), the exchange of best
practices (n = 8), and published scientific reports which
influenced EU policy-making (n = 7) were ranked on the
first three positions.
Achievements, missed opportunities, failures
At a glance, the label “achievement” was allocated to the
public health mandate as it is laid down in the Treaties,
the establishment of EU-level agencies dealing with public
health topics and successes in smoking prohibition, food
safety and infectious disease control. The label “missed
opportunity” was allocated to the insufficient degree to
which the HiAP approach is implemented and the ways inwhich health promotional aspects of alcohol and nutrition
were handled. The label “failure” was less often assigned
with the missing integration or link to social policies
appearing in some interviews under this heading as well
as the strength of the internal market which annulled
national protective alcohol legislations in some member
states. In Table 4, we provide the full list of EU-level
outputs or actions which, based on the content analysis
and the identified thematic categories, were mentioned
as achievements, missed opportunities or failures by the
key informants. Due to a broad and divergent spectrum
of perceptions, topics almost always shared aspects of
achievements, missed opportunities or failures. In the
following section, we focus on those EU-level outputs
or actions which were mentioned by the majority of re-
spondents during the interviews and allowed us to draw
a comprehensive picture on the breadth and the diver-
sity of expert perceptions.
EU health policy - an overview
An assessment of the general value of EU-level public
health actions over the last twenty years resulted in
mainly ambivalent judgments. On the one hand, many
relevant activities were performed at an EU-level and
the existence of a health mandate contributed to an EU
social model. On the other hand, its dependence on pol-
itical will and economic circumstances influenced the
development of EU-level public health policy and led to
the perception that more should or could have been
achieved within and beyond the possibilities of the current
health mandate.
The role of the Directorate General for Health and
Consumers
The establishment of the Directorate General for Health
and Consumers (DG SANCO) in 1999 as an independent,
formal structure for EU health policy was generally dis-
cussed as an achievement. The formation of DG SANCO,
and thus, the political decision to separate the health
dossier from DG V, the former DG with the responsibility
for health policy as well as a focus on employment and
social policies, was controversially perceived. The estab-
lishment of DG SANCO led, on the one hand, to a more
mature health policy field.
“…the DG V was a big DG and then DG SANCO
became separate from that. Health had its own
commissioner, its own opportunity to protect itself
and public health benefits.” (#15, public health
advisor/advocate)
On the other hand, aspects of failure were mentioned
regarding the detachment of health and social policy at
EU-level. According to the respondents being separated
Table 3 Ranking of influential policy outputs of EU-level public health policy, March/April 2012
Categories N
Secondary legislation and court decisions
Patients' rights decisions by the European court of justice 12
Directive on patients’ rights in cross-border care 10
Directive on tobacco advertising 9
Directive on blood safety 5
WHO Framework Convention on Tobacco Control 4
Directive on professional qualifications 3
Regulation 1408/71 3
Directives on tobacco products 2
REACH regulation of chemical substances 2
Soft laws, strategies and programmes
First and second public health programme 9
Together for health: 2008-2013 6
Framework for action in the field of public health 5
Towards modern, responsive and sustainable health systems (2011/C 202/04) 5
Europe 2020, Europe’s growth strategy 5
Health in All Policies 4
Information to Patients 3
Open Method of Coordination 3
Solidarity in health: reducing health inequalities 3
Council recommendation on patient safety 2
Framework Programmes on health research 2
White paper on governance 2
Green paper on the European workforce for health 0
Agencies, centres, organizations
European Medicine Agency 15
European Centre for Disease Prevention and Control 13
European Food Safety Authority 9
European Observatory on Health Systems and Policies 6
European Agency for Accreditation of Education in Public Health 1
European Chemicals Agency 1
European Foundation for the Improvement of Living and Working Conditions 1
European Monitoring Centre for Drugs and Drug addiction 1
Social Protection Committee 1
European Commission Food and Veterinary Office 0
European Commission Joint Research Centre institutes 0
Health Intergroup at the Committee of the Regions 0
Networks, policy platforms, cooperation
European presidencies 13
Cooperation EC with OECD and WHO 8
European Health Policy Forum 6
Network epidemiological surveillance and control of infectious diseases 6
Network on Health Technology Assessment 6
European Platform for Action on Diet, Physical Activity and Health 3
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Table 3 Ranking of influential policy outputs of EU-level public health policy, March/April 2012 (Continued)
eHealth Network 2
European involvement in GATS discussion 2
European Committee of Experts on Rare Diseases 2
European Platform against Poverty and Social Exclusion 1
European Innovation Platform on Active and Healthy Ageing 0
European Network of Health Promoting Schools 0
Joint Action Health Workforce Planning 0
Others
Work on health determinants 10
Best practice exchange 8
Scientific reports that influenced European policy-making 7
Budget of the European Union 5
Common Agriculture Policy reform 4
Alcohol regulation 3
HEIDI data tool 2
Initiatives on Roma and excluded groups 1
Project database on DG SANCO website 1
Work on public health core competencies by ASPHER 1
ASPHER: Association of Schoold for Public Health in the European Region.
DG SANCO: Directorate General for Health and Consumer Protection.
EC: European Commission.
GATS: General Agreement on Trade in Services.
HEIDI: Health in Europe: Information and Data Interface.
OECD: Organization for Economic Cooperation and Development.
WHO: World Health Organization.
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policies and actions in health systems and healthcare at
EU-level.a
Following the formation of DG SANCO, it was seen as
a beneficial way forward for the DG to shift its sectorial
policy approach from a focus on specific topics such as
cancer, drug dependence, health monitoring, accidents
and injuries, or pollution-related diseases, to a horizontal
one with the formulation of the first health strategy with
three cross-cutting objectives: health information, health
threats and health determinants [46].
“And this was an important moment in time where
the sectorial approach to AIDS, cancer and other
issues has been reduced gradually and that more the
integral horizontal approach, which was applied at
that time already in all member states – hence Europe
was running behind in that sense, but ultimately was
embraced and taken as guideline for the framing of
all sorts of public health actions. “(#02, EU/national
civil servant)
Since it fostered more visibility of the public health
field and closer cooperation by financing projects, joint
actions and research across Europe, the Public Health
Programme of DG SANCO was commonly discussedas being supportive to the development of European
public health and the mobilization of the public health
community.
Aspects of missed opportunity became relevant when
assessing the representation of health in other EU policies.
“I don’t know what exactly the reason is, but they [DG
SANCO] are not strong enough to push for health in
[the other] DGs. The obvious example is the latest EU
2020 strategy, you cannot find reference to health
anywhere it’s really a disaster, because of [the] weak
DG SANCO. Health is not among the headline targets,
it’s not among the flagships.” (#15, public health
advisor/advocate)
While the cooperation with other DGs was recurrently
discussed as problematic, the potential for the “Partner-
ship on Active and Healthy Ageing” under the European
Innovation Union appeared as a unique theme and was
regarded as an achievement for strengthening health pol-
icy on the general EU policy agenda.
“…it is now coordinated under the Innovation Union
[of Europe2020], and so Commissioner Neelie Kroes
[DG Connect and Vice-Commissioner] is as much in
the lead as Commissioner John Dalli [DG SANCO].
Table 4 Summary of public health relevant EU-level actions and their perception as achievement, failure or missed opportunity
Topics Achievement Missed opportunity Failure
Treaty Inclusion of the health mandate as
enshrined in Article 129 of the Treaty
of the European Union.
Missing implementation of a connection/share
of power between economic and social EU policy.
Directorate general for health
and consumers (DG SANCO)
Existence and persistence of DG SANCO. DG SANCO is not strong enough to push health
in other DGs.
DG SANCO set-up: Missing link to social policy.
Public health programme. Public health did not become a key aspect of
EU policy.
Sustainability development strategy: DG SANCO
is not playing an active role in the marketing of
the strategy.
Cooperation Cooperation between EU, WHO and OECD. Missing connection and joint forces between EC
and WHO.
EC agencies Development of agencies: ECDC, EFSA,
EMA, EMCDDA.
ECDC Legislation on infectious disease control. ECDC mandate should include responsibilities
in risk management of infectious diseases.
European Programme for Intervention
Epidemiology Training (EPIET).
ECDC profile should cover also non-communicable
diseases and SDoH.
EMA Coordination of the approval of efficacy,
safety and quality of drugs.
Cost-effectiveness of pharmaceuticals is not taken
into account.
Problem of not being able to tackle pharmaceutical pricing.
Reversal of the approval of already approved
drugs not handled on EU-level.
EFSA Control of health claims of food products. EFSA mandate should include/be stronger on
health promotion aspects of nutrition
(e.g. regulation of advertisement of unhealthy
food products).
Food safety Directive.
Health in All Policies (HiAP)
approach
Health mandate assures that health
protection should be guaranteed in
all EU policies.
HiAP and Health Impact Assessment have never
been implemented fully (tick box exercise).
Leads to the discussion of health in
other sectors.
Lifestyle factors Common tobacco legislations in Europe
(WHO Framework Convention of Tobacco
Control; tobacco product-; tobacco
advertising Directive).
The tobacco regulations could have been designed
stronger (e.g. more harmonized realisation of smoking
prohibition on public places).
Tobacco regulation has some aspects of failure since a strict,
general ban is not reached.
Food safety measures and regulations
on health claims.
Missing political will to tackle obesity and related
life style factors like unhealthy food products.
Health Research Programme EU health research budget and outcomes
of the programme.
Missing integration of the research programme and EU health



















Table 4 Summary of public health relevant EU-level actions and their perception as achievement, failure or missed opportunity (Continued)
EU budget Largest budget proportion shifted in the
Multiannual Financial Framework 2007–2013
from agriculture financing to the funding
of cohesion and sustainable growth policies.
Health research budget.
The use of Structural Funds for investments
in health (2007–2013).
Internal market provisions Internal market rules as source for legislation should
be more attentive to health concerns.
Internal market provisions cause problems if member state
regulation is more protective regarding health threats than
EU regulation.
Patients’ rights directive The patients’ rights Directive in general. Negotiations on patients’ rights Directive failed to
include a strong emphasis on the development of
common standards.Effect on cross-border cooperation.
Gives legal certainty to policy makers.
Common Agriculture Policy Policy field which starts to recognize health,
e.g. in its white paper on the CAP after 2013
(2009/2236(INI)).
Unrecognized potential for health of the CAP by
public health sector.
Health information Health life years as indicator in the
Lisbon strategy.
Missing health information system.
Lack of morbidity data.
Different public health topics
health inequalities EC communication: solidarity in health:
reducing health inequalities in the EU.
HTA Strengthening of the HTA approach in the EU. Coordinating cross-country level health technology
assessments.
Rare diseases Coordinated management of rare diseases.
Tuberculosis Existing drug resistance of tuberculosis as indicator for lacking
disease management.
Health of minorities Health of minorities (e.g. Roma) as part of
the European agenda.
Social care Social care is hardly seen as EU competence.
Environment (and health) Environmental standards set by the EU. Missing follow-up process on the Environment and
Health Action Plan (2004–2010).
Information to patients Blocking of direct to consumer advertising
of prescription-only pharmaceuticals.
Governmental issues White paper on governance (2001)
increased transparency.
More standardisation of methods (evaluation




















Table 4 Summary of public health relevant EU-level actions and their perception as achievement, failure or missed opportunity (Continued)
Increased understanding of the public health
community about the impact of EU policies on
public health.
Industry involvement Cooperation with industry influences the health research
agenda and policy-making.
Evidence-based policy-making: the interest of the industry
is against public health.
ECDC: European Centre for Disease Prevention and Control.
EFSA: European Food Safety Authority.
EMA: European Medicines Agency.
EMCDDA: European Monitoring Centre for Drugs and Drug Addiction.
HTA: Health Technology Assessment.
DG: Directorate General.
SDoH: Social Determinants of Health.
EC: European Commission.
OECD: Organization for Economic Cooperation and Development.
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sorts of partnerships on specific policies, then I think,
we’ll get a better understanding.”(#04, EU/national
politician)
With regard to assessing the status of DG SANCO co-
operation with other international policy actors, respon-
dents had mixed perceptions. Whereas some argued that
DG SANCO’s collaboration with international organiza-
tions like the WHO-EUR or the OECD is improving
and therefore, can be considered as an achievement,
others asserted that this collaboration was not suffi-
ciently established and can therefore be categorized as a
missed opportunity.
The role of health agencies: the example of ECDC
The establishment and the work of EU public health
agencies like the EMA, the ECDC, the EFSA, and the
European Monitoring Centre for Drugs and Drug Ad-
diction (EMCDDA) were regarded as an achievement
and as an important step forward towards the strength-
ening of the European dimension in health. The work
and the scope of the agency mandates was a recurring
topic and subject to diverging perceptions. As an ex-
ample, in the case of the ECDC, its development was
assessed as an achievement whilst its scope was consid-
ered a missed opportunity.
The bioterrorism attacks on the United States of
America in 2001 and the SARS crisis led to calls for better
international coordination of infectious disease surveil-
lance and the establishment of ECDC in 2004 [47]. Hence,
the setting up of ECDC was commonly perceived as an
achievement, since it gave preceding EU actions in infec-
tious disease control a formal structure and maintained
actions in the field. Also, the close collaboration with the
respective national public health agencies during out-
breaks and in negotiating and developing common guide-
lines for infectious disease control were regarded as an
important task of the ECDC.
However, a number of respondents were critical of the
scope of the ECDC mandate and thus, looked at this as
a missed opportunity. Questions were raised on whether
the ECDC’s responsibility in surveillance, risk assessment
and training are sufficient or if additional responsibilities
in risk communication and management were needed
to assure full stewardship during and in the prevention
of health crises.
“I suppose the flu epidemic […]. That should be put on
the table not only as a missed opportunity, big failure,
having put ECDC at the center of the development,
but the ECDC is not authorized to risk
communicational management as you know. So, in
that sense, it is a failure that member states were notable to coordinate in this very important public health
area and use the EU institution, either ECDC or WHO
to do that.” (#03, public health advisor/advocate)
Moreover, interview participants reported tensions be-
tween member states and EU agencies regarding the trans-
fer of responsibilities from national to EU-level.
“And the member states are very reluctant to hand
over power regarding public health to the Commission,
or to Brussels. Now if you focus on infectious diseases,
that is much better because they understand that there
is a need, but again it is not easy.” (#30, EU/national
civil servant)
Since the largest burden of disease in the EU is caused
by non-infectious rather than infectious diseases, a call
was put forward to further increase the mandate of ECDC
to all public health relevant aspects and not focus only on
infectious diseases.Health in All Policies (HiAP)
The HiAP approach was generally assessed as an achieve-
ment regarding its potential to address health determi-
nants outside the health sector.
“[the article on the health mandate] is very important,
because thereby a mandate is created that the
Commissioner for Health and Consumer Affairs […]
approaches his colleagues whenever they make new
legislation to ensure that the health protection
dimension is guaranteed; it gives partly a mandate to
break into the policy and law development in sectors
which in principle do not have any links with public
health. […] this is very difficult. But its potential is
very strong.” (#2, EU/national civil servant)
However, in regard to its degree of implementation
participants commonly perceived HiAP as a missed op-
portunity. Health Impact Assessment, the implementing
tool to HiAP, was regarded as a “tick box exercise” (#03,
#15, both public health advisor/advocate) rather than a
thorough consideration of health in other policies areas.
Explanations given during the interviews demonstrated
that conditions to achieve HiAP seemed not to be estab-
lished yet and that there seems to be difficulty in bring-
ing DG SANCO interests in line with the interests of
other DGs without over-emphasizing the health aspect.
Political assertiveness in convincing other Commissioners
and DGs about the relevance for intersectoral cooperation
was perceived to be lacking, even though an Inter-service
group on Public Health with the participation of more than
twenty EC departments was established for this purpose.
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Generally, the work regarding tobacco was regarded as
an achievement of how European health policy-making
effectively addressed a life style risk factor for health.
“The progress around tobacco [Directive on tobacco
advertising, Directive on tobacco products, transparency
register], the fact that we have a piece of international
law on tobacco [WHO Framework Convention on
Tobacco Control] is massive and that was European
led.” (#05, public health advisor/advocate).
This quote echoed the perception of the majority of
respondents who emphasized the leading role of the EU
regarding the support and commitment to the WHO
Framework Convention on Tobacco Control. Moreover,
it was argued that the achievements regarding the regu-
lation of tobacco advertising and smoking prohibition in
public places would not have been achieved by single
member states independently and thus this was a com-
mon achievement initiated and supported by European
cooperation. Nevertheless, aspects of a missed opportunity
or even failure were mentioned in this regard since some
would have appreciated stronger legislative measures to
achieve a more harmonized realization of smoke-free
legislation across the EU.
It was considered that the achievements recognized in
EU tobacco legislation were missed in the regulation of
other health-related life style factors such as nutrition
and alcohol. Whilst regulations in the area of food safety
were generally acknowledged as an achievement by pre-
venting food-borne health threats; a potential mandate
to address the composition of food and thereby, prevent,
inter alia obesity or non-communicable diseases seemed
to be neglected and was labeled as a missed opportunity.
“…food safety has been majorly put forward over the
last twenty years, in the sense that we know that the
food will not be contaminated. But then it is a missed
opportunity in the sense that beyond food safety there
is health promotion and then one wanted the Union to
have more powers to regulate issues on the content of
saturated fat for instance or the percentages of sugar
and so on.” (#03, public health advisor/advocate)
With regard to governmental activity on these issues,
the EU Platform for Action on Diet, Physical Activity
and Health was named as an example of an achievement
as well as a failure.
“I think the diet platform […] can be seen as a failure
and opportunity. […] If we had not created that
platform then arguably the issue wouldn’t have been
tackled at all. And in a way that has been reallybrought some issues of complexity to the political
discussion around issues around marketing of food,
around self-regulation, reformulation, some of the
initiative like salt in diet has come as a commitment
from that platform.”(#05, public health advisor/
advocate)
The failure aspect of the EU Platform for Action on
Diet, Physical Activity and Health was related to the per-
ception that a platform is a rather weak policy instru-
ment and that more political will to tackle these issues
with stronger EU policy or legal instruments would have
had more impact.
Additionally, the lack of timely cooperation of public
health professionals with other sectors such as agricul-
ture was raised as missed opportunity. It was illustrated
that agriculture policy has public health relevant links
regarding affordability, accessibility, and the availability
of food. However, it was also argued that this cooper-
ation has been developed further over the recent years.
“And it is correct, that the Common Agriculture Policy
has not been taken up health in the beginning, but by
now they are doing this very consciously. […] Thus, I
really see an improvement; I actually do not see a
situation anymore in which health was influenced
really negatively [by the Common Agriculture Policy].”
(#26, EU/national civil servant)
Internal market provisions
Internal market provisions were perceived as ambivalent
by the respondents. The EU is based on internal market
rules that also affect EU health policy.
“The engine of European health policies is still the
market.”(#23, academia)
However, the influence of EU market regulations, for
example on alcohol policies, was perceived as a failure
when member states had more protective and stricter
national legislation as was the case in the Nordic coun-
tries. Respondents claimed that EU internal market reg-
ulations that are more attentive to health issues would
be appreciated in this case. Moreover, the potential given
by Articles 36 and 114 of the TFEU, which put limita-
tions on the Single Market, was mentioned and it was
perceived as a missed opportunity that this potential had
not been fully taken up by public health experts:
“[…] the public health aspect, which is written into
Article 95 [now Article 114, TFEU] on the internal
market, you can put limits on the internal market on
the grounds of public safety, public morality and
public health, is almost never used. What if DG
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weapon?” (#32, public health advisor/advocate)
This was positively exemplified by the case of tobacco
control which applied internal market rules for public
health purposes to assure harmonized labeling, pack-
aging, nicotine content, etc. across the EU. However,
the application of the health argument to put limitations
on the internal market rules was also perceived as being
negatively connoted by non-public health experts:
“If you just go to the DG Internal Market and grab the
first person you see and ask them what public health
means, they will tell you it’s the exception member
states use to defend local weird monopolies on
peculiar alcohol, or something like that. It’s an
exception to a rule.” (#19, academia)
Patients’ rights Directive
The recent EU patients’ rights Directive in cross-border
healthcare [39] was mainly regarded as an important
achievement. This assessment was not necessarily driven
by satisfaction with the scope of the Directive but, in-
stead, because it is the first EU secondary legislation
ever enacted specifically on healthcare.
“[…] the cross-border Directive will turn out to be
incredibly important. Particularly because it is so
symbolic important if you like because it does represent
really the first time that the EU has got any concrete
in relation to healthcare as opposed to public health.
The consequences of this remains to be seen.” (#29,
EU/national civil servant)“Therefore, I see the patients’ Directive as a true
success from a legislative perspective” (#23,
academia)
The achievement aspect was supported by perceptions
that the Directive will lead to more cross-border co-
operation and will have an impact on quality of care as
well as on priority setting in healthcare and the pack-
aging of healthcare services. Thereby, it was expected
that the Directive will not only influence people who
seek healthcare services in other countries but also
those who seek services in their home country. In this
regard, some expected that the Directive would also ul-
timately empower patients as consumers of healthcare
services.
“The cross-border Directive […] will have consequences
of more consumer empowerment, consumer rights,
patient rights, more consumer participation and
more literacy,…”(#03, public health advisor/advocate)However, there were also critical voices that interpreted
the Directive, as targeting a limited segment of the
European population and hence, potentially increasing
health inequalities. These respondents also questioned
the willingness of the general population to seek health-
care treatment outside their home country. Furthermore,
respondents were critical of the extent to which more EU
involvement in healthcare of member states would lead to
quality assurance in general:
“It is positive in the way people can be treated where
they want, but it is still my point of view that we […]
want to have our own level of quality and we don’t
want others to decide what level it should be. Perhaps,
because we have a very high quality […]. But of course
we don’t mind to tell others about it, we don’t mind
others to come in, we don’t mind to help others to get
the same standard - that is cooperation, so I always
say I love cooperation but I do mind the
harmonization.”. (#18, EU/national politician)
Discussion
This study provides an overview of public health rele-
vant EU-level actions of the past twenty years. We out-
lined the diverse nature of expert perceptions on key
developments in the field and provided a ranking of the
most influential achievements. The assessment of out-
puts or actions being an achievement appeared across
and within interviews along with assessments of outputs
or actions being a missed opportunity and less often a
failure. Thereby, it turned out that the EU public health
field has significantly developed its organizational struc-
tures (DG SANCO, supranational agencies dealing with
public health) and incorporated public health topics like
infectious disease control and tobacco control, whereas
the HiAP approach still included untapped potential. This
finding confirms “The Challenge of Implementation” [48]
of the HiAP concept in the EU [28,49]. Given the fact
that according to Article 9 and Article 168 (1),TFEU [1],
a high level of human health protection should be ensured
within all EU policies and actions, it was seen as a weakness
that the uptake of health consideration in the general EU
policy-making process was low [28]. Ollila described the
importance of communication and cooperation strategies
for a successful realization of the HiAP approach [49]. The
deficiency of these strategies was raised during the inter-
views which indicated that the performance of EU health
players is perceived to be particularly poor in this regard.
Concordance of interview responses with tasks
formulated in the health mandate of the EU
Interestingly, the study indicated that the Treaty-based
tasks such as support of cooperation between member
states, development of guidelines and indicators, best
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on EU-level public health to ensure ‘a high level of human
health protection’ [1] were only partially perceived as
fulfilled or acknowledged by the interviewed experts.
Thematic discussions on actions or policies related to
the development of guidelines and indicators appeared
with regard to infectious disease surveillance and man-
agement of rare diseases but were not a major theme
across interviews. The EU-level task to promote best
practice exchange among member states was regarded
as influential, which is represented by a top position in
one of the rankings presented in this paper. With re-
gard to the task of establishing monitoring and evalu-
ation structures, some respondents perceived the status
of the EU health information system rather as a failure.
This corresponds to observations in the literature indicat-
ing that although ground work such as the development
of a common EU health indicator set is acknowledged
[50,51] further efforts are needed to implement and main-
tain health indicators [51] and to develop a permanent
and sustainable EU public health monitoring and report-
ing infrastructure that supports decision making in public
health on EU level [50,51]. Respondents agreed that co-
operation in the area of public health between member
state representatives and experts as well as with other
stakeholder groups has increased and has been facilitated
by the EU through various projects, networks, forums,
and platforms. This trend was mainly positively perceived
since it supported EU-level public health policy by accu-
mulating and exchanging knowledge, generating public
support and a legitimacy to act on certain fields [3]. This
finding is corroborated by the literature on the potential
of new governance instruments for health- and social
policy-making at EU-level [11,52-54]. However, these new
governance instruments can also be regarded as a rather
strategic investment of the EC to keep topics on the
agenda until a political window of opportunity opens but
as an ineffective policy tool to enforce and implement
action in due course [6]. The collaboration of a diverse
set of stakeholders as it is the case for example in the
EU Platform for Action on Diet, Physical Activity and
Health can lead to actions that constitute rather a com-
promise of various interests. Consequently, the results
might be disappointing from the viewpoint of public
health experts [6,55]. A final judgment on the impact of
facilitating collaboration is to be awaited and may only be
made in the long term future. It will require different ways
of measuring ‘impact’ compared to the analysis of domes-
tic adaptations when implementing EU hard law [56].
Characteristics of EU health policy that influenced
experts’ perception
The assessments of EC tasks for public health policy
making have been influenced by characteristics like thesubsidiarity principle throughout several interviews. On
the one hand some participants were in favor of more
EU influence on health policies and their implementa-
tion. In their view integration and harmonization of
health policy did not reach far enough and hence their
perception of actions was dominated by the category
‘missed opportunity’. On the other hand some experts
were in favor of keeping certain health issues like health
care as national responsibility which led to a perception
of too much EU involvement and a negative perception
of the evolvement of the health mandate.
Public health has a cross-cutting nature and cooper-
ation across DG’s often poses difficulties. Therefore, con-
vincing evidence is required to demonstrate the health
impact of policies outside the health domain and strong
partnerships are needed to counter strong industrial lobby-
ing groups [6,57,58]. The ease of cooperation and the po-
tential to achieve policy coherence between DG SANCO
and DGs with stronger regulatory competences like the
internal market (e.g. regarding tobacco, pharmaceuticals)
or agriculture policy (regarding food safety, subsidies of
unhealthy versus healthy food products) represented
another characteristic that influenced the individual per-
ception of EU public health policies. Experts who assessed
the value of EU health policy actions under the reality of a
rather weak health mandate were more likely to perceive
EU actions as achievements. This was in contrast to others
who strove for more appreciation of social and health
matters in EU policies and who perceived a lot of missed
opportunities or failures in this regard as the power of the
EU was too weak to realize change and to fulfill the ob-
jective of the health mandate to ensure human health
protection for citizens in the EU.
In summary, underlying themes such as cooperation
among European public health professionals, increasing
institutionalization, and characteristics such as the issue
of subsidiarity or the possibilities to cooperate across EU
policy domains influenced experts’ perceptions through-
out the topics presented in this paper. These conditions
and characteristics are part of what Lamping called the
“chaordic dynamics” of European integration in the field
of health policies [3]. As our study demonstrated EU
health policy does not demonstrate a clear-cut success
since the logic of action in the field can involve diverging
interests. Nevertheless, the EU public health has quite
systematically developed in terms of scope and impact
beyond the original mandate.
Limitations
The ranking of influential policy outputs provided indi-
cations on important developments in EU public health
policy. However, even though we categorized the out-
puts, they sometimes differed in character and power
which might have led to imbalanced judgments.
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EU-level actions or policies as achievements, missed op-
portunities or failure for public health. Some were identified
because they increased the strength or value of EU-level
public health policy, whereas, others were identified because
they impacted the health of the European population.
The findings of the study may not be empirically
generalizable since they were closely linked to qualitative
individual perceptions and the settings that participants
belonged to. However, we are confident that the broad
range of profiles of the experts has ensured the diversity
of perceptions on the topics varying from achievement
to missed opportunity and failure. Moreover, given that
participants were generally active in health policy at EU-
level and mainly positive about the EU, this could also
have influenced the obtained results to some extent.
Conclusion
EU public health policy is subject to divergent percep-
tions of how successful or unsuccessful specific topics
have been tackled and how far European integration in
public health policy should go. From the findings, it is
unequivocal that the EU has strengthened its role over
the past twenty years in supporting, coordinating, and
supplementing member states’ actions on public health
issues as laid down in Article 168 (2), TFEU. The EU is
now a recognized player in public health in Europe. How-
ever, when it comes “to the promotion of a high level of
[…] protection of human health […]in defining and imple-
menting its policies and activities” (Article 9, TFEU), fur-
ther work is needed to achieve the full potential of the EU
health mandate.
Endnote
aAlso several EU member states disconnected on national
level the Ministry of Health from Social Affairs. At the time
of writing only seven out of 28 EU member states orga-
nized health and social affairs within one ministry (Spain,
France, Sweden, Finland, Estonia, Greece, the Netherlands).
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